Navigation Links
Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Date:10/22/2007

SANTA MONICA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an update on its testing of Rh-Apo2L, the next large-scale product to be launched by the Company into the China market. Aida previously announced that it had successfully passed its Phase I tests in July 2006, which consists of tests for safety, dosage and the potential cancer treatments to be tested in Phases II & III. Aida is currently undergoing Phase II testing of Rh-Apo2L testing through China's SFDA, the national drug regulatory agency.

Phase II is divided into two substages: IIA and IIB. IIA consists of tests on over 100 human patients using only Rh-Apo2L and gauges the efficacy of the drug as well as the narrowing of the scope of targeted cancers. Results thus far have shown strong efficacy in treating lung cancer (non-small cell), non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer. Shanghai Qiaer, Aida's research subsidiary, has reduced the key cancer targets to the three main diseases which Rh-Apo2L has shown the most efficacy and which have the most market potential. These three cancer targets will be announced at a later date, pending successful trials. Formal results will also be released after clinical tests are completed.

Phase IIB is testing Rh-Apo2L in combination with other anti-cancer drugs on the above three chosen diseases. The tests monitor interaction with other drugs, side effects and dosages for additional tests. To date, the combined use of Rh-Apo2L with selected anti-cancer drugs has shown good efficacy, reliable safety and no additional side effects. Tests are still ongoing for various dosage amounts on different types of cancer and no regulatory approval has been received for these drugs.

About Rh-Apo2L -- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. This biopharmaceutical drug has gained
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. What patients want: A story of choice, clinical trials & evidence-based medicine
3. ZyStor seeks to raise $15M for clinical trials
4. Prodesse begins clinical trials for flu virus detection
5. ConjuGon raises $3.3 million to fund clinical trials
6. Cancer-fighting agent heads for clinical trials
7. Quintessence cancer treatment chosen for clinical studies
8. Third Wave reports clinical growth, continued loss
9. Childrens expanding use of Sunrise Clinical Manager
10. Life-sciences conference to feature novel research with clinical potential
11. $14 million grant to drive clinical research at UW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... DUBLIN , May 05, 2015 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. Macromolecules ... acids undergo separation or are broken into ... biotechnological products. This separation requires various advanced ...
(Date:5/5/2015)... May 5, 2015  Tikcro Technologies Ltd. (OTCQB: ... to continue trading on OTCQB  Marketplace, the market ... Marketplace allows for a continuous public market for ... have real-time quotes and market information on us ... OTCQB Marketplace includes U.S. and international companies in ...
(Date:5/5/2015)... 5, 2015  Renova™ Therapeutics, a biopharmaceutical company ... and other chronic diseases, has engaged RAND Health ... to reflect the healthcare patterns of multiple advanced ... be used to characterize the impact the company,s ... those groups of patients and the overall health ...
(Date:5/5/2015)... May 5, 2015 ImmunoCellular Therapeutics, Ltd. ... Gengos , President and Chief Executive Officer, will ... DATE:  Thursday, May 7, 2015     TIME:  11:30 ... > click the red "register/ watch presentations" ... interactive online event where investors are invited to ...
Breaking Biology Technology:Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2
... testing market is projected to grow at a healthy pace to ... growing incidence of genetic diseases and growing consumer awareness and rising ... ... (PRWEB) October 30, 2008 -- Genetic testing, which of-late has been ...
... at the National Institute of Standards and ... microscope to quickly and cheaply analyze nanoscale ... Scanning Optical Microscope (TSOM) imaging, the technique ... control and biotechnology. , Optical microscopes are ...
... PALO ALTO, Calif., Oct. 29 Telik, Inc.,(Nasdaq: ... an interrupted Phase 3,randomized study of Telcyta (canfosfamide ... PLD alone in second-line,therapy in platinum refractory, primary ... of platinum status are,provided below)., On an ...
Cached Biology Technology:Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3Nanoscale dimensioning is fast, cheap with new NIST optical technique 2Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 2Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 3Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 4
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... forever change the way some of the most widely used ... Science , he and his partner in the research, ... a reality. The discovery appears in the October 28, 2011 ... synthesis of homogeneous ultra-low molecular weight heparins." Linhardt, the ...
... Naval Research (ONR) will promote its science and technology ... (HACU) 25th Annual Conference, Oct. 29-31, in San Antonio. ... the Department of the Navy,s (DoN) science and technology ... funding, internship and fellowship opportunities. It is aimed at ...
... how mice recover after H1N1 flu, researchers at Harvard Medical ... A*STAR of Singapore, have cloned three distinct stem cells from ... can form into the lung,s alveoli air sac tissue. What,s ... are rapidly deployed in a dynamic process of lung regeneration ...
Cached Biology News:Discovery announced in Science represents 'new paradigm' in the way drugs can be manufactured 2Discovery announced in Science represents 'new paradigm' in the way drugs can be manufactured 3Lung stem cells offer therapeutic clues 2
...
... PI is used in conjuction with Annexin ... the earlier stages of apoptosis (Annexin V ... in later stages of apoptosis or already ... is detected in the orange range of ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... a software package that provides crystallographers ... custom buffer creation, set-up of experimental ... trials. The software helps crystallographers through ... protein crystallography: Design ...
Biology Products: